Search research articles
Contact Us
Filters
Showing results (51-60 of 63) with videos related to
Page
of 7
Sort By:
Oncogene
|
May 31, 2022
Correction: ATR and CDK4/6 inhibition target the growth of methotrexate-resistant choriocarcinoma
Marina Georgiou, Panagiota Ntavelou, William Stokes, et al.
Oncogene
|
March 18, 2022
ATR and CDK4/6 inhibition target the growth of methotrexate-resistant choriocarcinoma
Marina Georgiou, Panagiota Ntavelou, William Stokes, et al.
Gynecologic Oncology
|
June 8, 2024
Feasibility and acceptability of a nurse-led telehealth intervention (BOLSTER) to support patients with peritoneal carcinomatosis and their caregivers: A pilot randomized clinical trial
Rachel A Pozzar, Andrea C Enzinger, Catherine Howard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 15, 2009
Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer
Ursula A Matulonis, Suzanne Berlin, Percy Ivy, et al.
Gynecologic Oncology
|
August 11, 2020
Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial
Elizabeth K Lee, Niya Xiong, Su-Chun Cheng, et al.
Gynecologic Oncology
|
December 18, 2017
Is chemotherapy always necessary for patients with nonmetastatic gestational trophoblastic neoplasia with histopathological diagnosis of choriocarcinoma?
Antonio Braga, Vanessa Campos, Jorge Rezende Filho, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 29, 2022
A Phase II, Two-Stage Study of Letrozole and Abemaciclib in Estrogen Receptor-Positive Recurrent Endometrial Cancer
Panagiotis A Konstantinopoulos, Elizabeth K Lee, Niya Xiong, et al.
JAMA Oncology
|
February 26, 2016
Genetic Basis for PD-L1 Expression in Squamous Cell Carcinomas of the Cervix and Vulva
Brooke E Howitt, Heather H Sun, Margaretha G M Roemer, et al.
Nature Communications
|
December 3, 2025
Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial
Panagiotis A Konstantinopoulos, Ningxuan Zhou, Richard T Penson, et al.
JAMA Oncology
|
July 28, 2022
Evaluation of Treatment With Talazoparib and Avelumab in Patients With Recurrent Mismatch Repair Proficient Endometrial Cancer
Panagiotis A Konstantinopoulos, Allison A Gockley, Niya Xiong, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 63) with videos related to
Sort By:
Page
of 7
Oncogene
|
May 31, 2022
Correction: ATR and CDK4/6 inhibition target the growth of methotrexate-resistant choriocarcinoma
Marina Georgiou, Panagiota Ntavelou, William Stokes, et al.
Oncogene
|
March 18, 2022
ATR and CDK4/6 inhibition target the growth of methotrexate-resistant choriocarcinoma
Marina Georgiou, Panagiota Ntavelou, William Stokes, et al.
Gynecologic Oncology
|
June 8, 2024
Feasibility and acceptability of a nurse-led telehealth intervention (BOLSTER) to support patients with peritoneal carcinomatosis and their caregivers: A pilot randomized clinical trial
Rachel A Pozzar, Andrea C Enzinger, Catherine Howard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 15, 2009
Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer
Ursula A Matulonis, Suzanne Berlin, Percy Ivy, et al.
Gynecologic Oncology
|
August 11, 2020
Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial
Elizabeth K Lee, Niya Xiong, Su-Chun Cheng, et al.
Gynecologic Oncology
|
December 18, 2017
Is chemotherapy always necessary for patients with nonmetastatic gestational trophoblastic neoplasia with histopathological diagnosis of choriocarcinoma?
Antonio Braga, Vanessa Campos, Jorge Rezende Filho, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 29, 2022
A Phase II, Two-Stage Study of Letrozole and Abemaciclib in Estrogen Receptor-Positive Recurrent Endometrial Cancer
Panagiotis A Konstantinopoulos, Elizabeth K Lee, Niya Xiong, et al.
JAMA Oncology
|
February 26, 2016
Genetic Basis for PD-L1 Expression in Squamous Cell Carcinomas of the Cervix and Vulva
Brooke E Howitt, Heather H Sun, Margaretha G M Roemer, et al.
Nature Communications
|
December 3, 2025
Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial
Panagiotis A Konstantinopoulos, Ningxuan Zhou, Richard T Penson, et al.
JAMA Oncology
|
July 28, 2022
Evaluation of Treatment With Talazoparib and Avelumab in Patients With Recurrent Mismatch Repair Proficient Endometrial Cancer
Panagiotis A Konstantinopoulos, Allison A Gockley, Niya Xiong, et al.
Page
of 7